Medicare Enrolled

Dr. Eric Rishe, MD

Hematology & Oncology · Pembroke Pines, FL
Speaking/Promotional
12309 PEMBROKE RD, Pembroke Pines, FL 33025
9175706945
In practice since 2007 (19 years)
NPI: 1023133550 verify on NPPES ↗
High
DATA COVERAGE
Data in 3 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Rishe from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Rishe? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Rishe

Dr. Eric Rishe is a hematology & oncology specialist in Pembroke Pines, FL, with 19 years of NPI registration.

Between the years covered by Open Payments, Dr. Rishe received a total of $62,158 from 61 pharmaceutical and/or device companies across 581 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Rishe is High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice $62,158 industry payments

Florida License Status

FL DOH · MQA
1
Active license
None
Board action on record
0
Recent admin complaints
Profession License # Status Expires Board Action
Medical Doctor 111691 Clear January 31, 2028
Data from Florida Department of Health Medical Quality Assurance. License records are public under Chapter 119, Florida Statutes. Verify directly on FL DOH →

Industry Payment Transparency

Open Payments through 2024 ↗
$62,158
Total received (2018-2024)
Avg $8,880/year across 7 years
Top 13% in FL for hematology & oncology
61
Companies
581
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$51,197 (82.4%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$10,142 (16.3%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$819 (1.3%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,376
2023
$2,633
2022
$2,116
2021
$3,496
2020
$4,751
2019
$11,894
2018
$35,892

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Amarin Pharma Inc.
$50,741
Janssen Biotech, Inc.
$1,439
E.R. Squibb & Sons, L.L.C.
$1,211
PFIZER INC.
$858
MACROGENICS, INC.
$819
Novartis Pharmaceuticals Corporation
$652
Celgene Corporation
$595
GENZYME CORPORATION
$551
AstraZeneca Pharmaceuticals LP
$541
Rigel Pharmaceuticals, Inc.
$507
Lilly USA, LLC
$370
Incyte Corporation
$353
Merck Sharp & Dohme LLC
$321
GlaxoSmithKline, LLC.
$276
Seagen Inc.
$254
ABBVIE INC.
$242
Merck Sharp & Dohme Corporation
$196
Eisai Inc.
$157
Myriad Genetic Laboratories, Inc.
$137
Genentech USA, Inc.
$128
Alexion Pharmaceuticals, Inc.
$127
Daiichi Sankyo Inc.
$120
JAZZ PHARMACEUTICALS INC.
$119
Karyopharm Therapeutics Inc.
$112
Ipsen Biopharmaceuticals, Inc
$89
Astellas Pharma US Inc
$86
Mirati Therapeutics, Inc.
$82
EMD Serono, Inc.
$81
Dova Pharmaceuticals
$58
Amgen Inc.
$54
Regeneron Healthcare Solutions, Inc.
$53
EISAI INC.
$49
Clovis Oncology, Inc.
$47
Takeda Pharmaceuticals U.S.A., Inc.
$47
Genmab U.S., Inc.
$45
ARRAY BIOPHARMA INC
$42
Deciphera Pharmaceuticals Inc.
$41
Octapharma USA, Inc.
$39
Janssen Pharmaceuticals, Inc
$39
Adaptive Biotechnologies Corporation
$36
TAIHO ONCOLOGY, INC.
$36
Teva Pharmaceuticals USA, Inc.
$32
Boston Scientific Corporation
$30
Organon LLC
$29
AbbVie Inc.
$25
Mylan Institutional Inc.
$25
Global Blood Therapeutics, Inc.
$23
Sirtex Medical Inc
$21
Jazz Pharmaceuticals Inc.
$20
Gilead Sciences, Inc.
$19
Cumberland Pharmaceuticals, Inc.
$19
Agios Pharmaceuticals, Inc.
$19
Spectrum Pharmaceuticals Inc.
$19
Advanced Accelerator Applications
$19
Amneal Pharmaceuticals LLC
$18
Heron Therapeutics, Inc.
$17
Taiho Oncology, Inc.
$16
Menarini Silicon Biosystems, Inc.
$15
RECORDATI_RARE_DISEASES_INC.
$14
Blueprint Medicines Corporation
$14
Smith & Nephew, Inc.
$13
Top 3 companies account for 85.9% of total payments
Associated products mentioned in payments ›
AKEEGA · ALUNBRIG · AVASTIN · AYVAKIT · Abraxane · BAVENCIO · BENDEKA · BLENREP · BOSULIF · CABLIVI · CALQUENCE · CHANTIX · CINVANTI · CYRAMZA · Cellsearch · DARZALEX · Doptelet · ELIQUIS · ELITEK · ENJAYMO · EPKINLY · ERBITUX · ERLEADA · Epkinly · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUTATHERA · LYNPARZA · Lenvima · Lunsumio · MARGENZA · MEKINIST · MYRISK · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · ONTRUZANT · ONUREG · OPDIVO · OPDUALAG · OXBRYTA · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · PYRUKYND · Pomalyst · QINLOCK · REBLOZYL · RETEVMO · ROLVEDON · RYBREVANT · Revlimid · Rezlidhia · Rubraca · SANCUSO · SARCLISA · SHINGRIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · SYLVANT · Santyl · TABRECTA · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TUKYSA · Tavalisse · Tecentriq · TheraSphere Y90 Glass Microspheres 10 GBq · Trodelvy · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · Vascepa · Venclexta · XALKORI · XARELTO · XPOVIO · Xtandi · ZEJULA · ZEPZELCA · clonoSEQ · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (82%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware.

Looking for a hematology & oncology specialist in Pembroke Pines?
Compare hematology & oncology specialists in the Pembroke Pines area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
201
Per 100K population
10.3
County median income
$74,534
Nearest hospital
SOUTH FLORIDA STATE HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data — No data N/A
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 3 of 4 available federal datasets, with a Data Coverage level of High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Rishe is a hematology & oncology specialist, with speaking/promotional industry engagement in the top 13% of FL peers, with 19 years of NPI registration.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Does Dr. Rishe receive payments from pharmaceutical companies?
Yes. Dr. Rishe received a total of $62,158 from 61 companies across 581 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
What does Data Coverage mean?
Data Coverage (currently High for Dr. Rishe) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →